Actively Recruiting
Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice
Led by Novartis Pharmaceuticals · Updated on 2026-05-05
240
Participants Needed
7
Research Sites
205 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is designed to evaluate the effect of using the application on the adherence of patients with luminal HER2- breast cancer (BC) stage II-III to adjuvant therapy with ribociclib in combination with an aromatase inhibitor (AI). The purpose of the app is to increase adherence to treatment by informing patients about the risks of relapse and adverse event prevention and treatment.
CONDITIONS
Official Title
Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female and male patients with histologically verified and radically treated stage II-III hormone receptor positive HER2-negative breast cancer
- Age 18 years or older at start of ribociclib therapy
- Prescribed ribociclib plus aromatase inhibitor (± GnRH agonist for premenopausal patients) within 28 days before signing consent
- Allowed to have started aromatase inhibitor therapy (± GnRH agonist) no earlier than 12 months before ribociclib start
- Provided written informed consent
You will not qualify if you...
- Currently participating in any interventional clinical study when signing consent
- Receiving active treatment for malignant neoplasms other than breast cancer at enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Novartis Investigative Site
Pskov, Russia, Russia, 180000
Actively Recruiting
2
Novartis Investigative Site
Moscow, Russia, 115304
Actively Recruiting
3
Novartis Investigative Site
Saint Petersburg, Russia, 194017
Actively Recruiting
4
Novartis Investigative Site
Saint Petersburg, Russia, 194291
Actively Recruiting
5
Novartis Investigative Site
Saint Petersburg, Russia, 197758
Actively Recruiting
6
Novartis Investigative Site
Sestroretsk, Russia, 197706
Actively Recruiting
7
Novartis Investigative Site
Ufa, Russia, 450054
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here